Nutriband Inc. (NASDAQ: NTRB) CEO Showcases AVERSA(TM) Abuse Deterrent Transdermal Technology At Emerging Growth Conference

• Nutriband sustains itself through multiple revenue-generating subsidiaries
• At the core of the company's innovation is the AVERSA(TM) platform, a proprietary abuse-deterrent transdermal technology
• AVERSA(TM) fentanyl is projected to achieve peak annual sales of $200 million upon FDA approval, with upside potential exceeding $800 million

The opioid crisis continues to highlight the urgent need for safer, more secure drug delivery methods, and Nutriband (NASDAQ: NTRB) is positioning itself as a company with a solution. At the August 2025 Emerging Growth Conference, Nutriband founder and president Serguei Melnik detailed the company's lead product, AVERSA(TM), an abuse-deterrent transdermal technology that integrates aversive agents to prevent misuse, abuse and accidental exposure of drugs with high abuse potential, particularly opioids (ibn/1qrav ). With AVERSA(TM), Nutriband is aiming to transform traditional transdermal patches into safer tools for patients who require powerful pain relief, while simultaneously reducing the risks that have fueled a national epidemic.

Melnik opened his presentation by highlighting the company's origins and growth trajectory since its founding in 2016. Nutriband, which completed its IPO in 2021, is structured differently from many biotechnology companies. Instead of relying solely on investor capital while burning through...

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company's newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: /Disclaimer

BioMedWire
San Francisco, CA

415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

MENAFN08092025000224011066ID1110032554